Articles tagged with Breast Cancer
A study published in JAMA Network Open found that half of all women will experience at least one false positive mammogram over a decade of annual breast cancer screening with 3D mammography. The risk of false positives is lower for women screened every other year, and non-dense breasts also show a lower false positive risk.
A study published in PLOS Medicine found associations between consuming artificial sweeteners and increased cancer risk. The researchers analyzed data from 102,865 French adults and discovered higher risks for overall cancer, breast cancer, and obesity-related cancers.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
A new study found that women have varying preferences for learning about their personal breast density, with higher rates among Non-Hispanic Black and Asian women. The study suggests that current breast density notifications may not meet the needs of all women, particularly those with lower literacy levels.
A new study reveals that the COVID-19 pandemic has led to significant declines in cancer screening rates across the US, particularly for colorectal, cervical, breast, and lung cancers. The American Cancer Society's National Consortium has announced nine recommendations to increase cancer screening rates and improve quality care.
Researchers developed a computational approach called CellTrek to combine parallel gene-expression profiling methods, creating spatial maps at single-cell resolution. The tool provides detailed information on individual cell types' location within tissues, enabling unique biological insights.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
A new AI tool has been developed to classify breast density on mammograms with high accuracy, overcoming limitations of visual classification. The tool, TRACE4BDensity, showed 89% accuracy in distinguishing between low and high density breast tissue, and was validated by external experts.
Columbia University researchers have engineered a microbial encapsulation system that temporarily hides therapeutic bacteria from immune systems, allowing them to deliver drugs to tumors and kill cancer cells in mice. The system, called iCAP, controls the bacteria's surface by manipulating gene circuits.
New research suggests that routine mammograms can provide key insights into a woman's risk of cardiovascular disease. The study found that detection of breast arterial calcifications on mammograms was associated with a higher risk of heart disease and stroke in postmenopausal women.
Scientists at George Mason University are developing a therapeutic drug to replace BRCA1 in women deficient, offering an alternative for patients resistant to tamoxifen. The team aims to define the structural features of BRCA1 and identify specific cancer stem cells to target, providing a personalized and precision medicine approach.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
Two clinical trials will report groundbreaking data on adjuvant olaparib for germline BRCA1/2 associated breast cancer and pembrolizumab for early-stage non-small cell lung cancer. These treatments aim to improve survival rates and reduce recurrence.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
A new study found that knowledge about breast density and its risks is linked to women's race/ethnicity and health literacy. While most women correctly understand some facts, significant variations were observed across racial and ethnic groups and health literacy levels.
A randomized Phase III trial showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with HR+ and HER2- metastatic breast cancer. The median survival was 63.9 months, and the six-year survival rate was 44.2%, compared to 51.4 months and 32% for placebo.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
Researchers developed a novel scaffold to grow breast tumors with reduced immune variability, enabling more accurate immunotherapy drug testing. The new model replicates treatment-resistant breast cancer microenvironments and predicts patient responses to therapy.
A research team at Huntsman Cancer Institute has developed new methods to identify personalized drug treatments for breast cancer. They have created a way to narrow the number of drugs that might be effective in each tumor based on its unique characteristics and behavior in laboratory models.
A modeling study suggests that breast cancer overdiagnosis may occur in about 15% of screen-detected cases, rather than the estimated 30%. This could spare around 25,000 women unnecessary treatment. Researchers used data from the Breast Cancer Surveillance Consortium to estimate the rate of overdiagnosis.
A study published in Nature Cancer has found that tissue damage caused by radiation can facilitate the spread of cancer, with neutrophils playing a key role. The researchers used mice to test the effect of high doses of radiation on healthy lung tissue and found that secondary tumours formed more easily in damaged lungs.
Researchers found that MYC inhibition by Omomyc exerts a dramatic effect on the metastatic process, reducing primary tumor and metastatic growth. The study suggests that MYC inhibition is anti-metastatic in breast cancer, offering promise as an anti-metastatic therapy.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
Annual MRI screenings starting at ages 30-35 may reduce breast-cancer mortality by more than 50% among women who carry certain genetic changes in three genes. The predictions involve pathogenic variants in ATM, CHEK2 and PALB2 genes – which collectively are as prevalent as the much-reported BRCA1/2 gene mutations.
Researchers investigated the association between family history of breast cancer and mammographic breast density among 14,000 premenopausal women. The study found a positive correlation between having a family history of breast cancer and higher mammographic breast density in these women.
A first-of-its-kind tool has been developed to help doctors better diagnose inflammatory breast cancer (IBC), a rare and aggressive type of breast cancer. The tool, which includes a quantitative scoring system, aims to increase diagnostic accuracy and predict outcomes, guiding treatment decisions.
A recent study published in JAMA Network Open found that the COVID-19 pandemic led to fewer early-stage and more late-stage breast cancer diagnoses. Researchers at UC San Diego Health surveyed patients with breast and colorectal cancers in 2019 and 2020, finding a significant increase in stage IV diagnoses.
Researchers compared early- and late-stage breast and colorectal cancer diagnoses before and during the pandemic at a California cancer center. The study found significant changes in diagnosis stages during the pandemic.
New studies from Michigan Medicine researchers aim to remove financial barriers for patients who receive abnormal test results, enabling them to complete the diagnostic process. The findings suggest that removing cost barriers could save lives by increasing screening uptake, particularly among women and underserved populations.
Research published in BMJ Open found that older women with higher oestrogen levels had a lower risk of severe COVID-19 infection and death. Women taking hormone replacement therapy also showed a significantly reduced risk of dying from COVID-19, highlighting the potential benefits of hormonal treatment in reducing infection severity.
Researchers found significant molecular differences in DNA repair genes and cellular signals controlling cell growth between healthy and tumor tissue of Black and white women. These differences may lead to improved treatment strategies for ER+ breast cancer, including earlier use of CDK inhibitors.
A new study by Virginia Commonwealth University researchers finds that triplatin is effective against triple negative breast cancer with high sulfated glycosaminoglycans (sGAG) levels. The drug accumulates inside cancer cells, causing damage and slowing tumor growth.
A new study published in The Lancet Oncology found that aromatase inhibitors are more effective than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal and postmenopausal women. Aromatase inhibitors were shown to be particularly beneficial for younger women, reducing the risk of recurrence by 30%.
The ACC cardiooncology course is designed to educate clinicians on improving awareness, identification, monitoring, and management of cardiovascular diseases in cancer patients. The course aims to help clinicians minimize cardiotoxicity from cancer therapies, leading to improved overall survival and quality of life for oncology patients.
Researchers used a patient's own immune cells to target unique mutations in tumor DNA, leading to measurable tumor shrinkage in 67% of patients with metastatic breast cancer. The approach has potential as a personalized treatment for hormone receptor-positive breast cancers.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
Researchers investigated geographic disparities in initial breast cancer care, finding significant regional variations and unequal distribution of resources. The study suggests that both patient-level factors and regional characteristics contribute to these disparities, affecting treatment outcomes.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
Researchers analyzed DNA sequences and electronic health records of thousands of individuals to discover that the chance a pathogenic genetic variant may cause a disease is relatively low, about 7 percent. However, some variants are linked to wide range of risks for disease.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers at Hiroshima University discovered that a broccoli compound, DIM, induces controlled cell death and recycling of cellular components in fission yeast. The study suggests that targeting the nuclear envelope could be an early target for future anti-cancer treatments.
Researchers have identified nine new factors involved in DNA repair, a critical process for human cell health. The findings can help develop new cancer drugs and improve existing therapies.
A study by Mayo Clinic researchers found that cancer patients receiving chemotherapy and targeted therapies may mount inadequate immune responses to COVID-19 vaccination. The authors recommend antibody level testing and booster vaccinations for these patients.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
Researchers at Duke University developed an artificial intelligence platform that analyzes potentially cancerous lesions in mammography scans. The algorithm is interpretable, showing physicians how it came to its conclusions, making it more trustworthy and useful for training students and aiding physicians in sparsely populated regions.
A study published in Cell Metabolism reveals unique features of brain metastasis in breast cancers, highlighting potential new targets for therapies. Researchers found that metabolically distinct cells have varying levels of glucose and glutamine usage, which can be targeted to reduce metastatic activity.
Researchers at Baylor College of Medicine have identified MAPK4 as a key player in triple-negative breast cancer growth and resistance to therapies. Eliminating or inhibiting MAPK4 reduces TNBC cell growth and sensitizes cells to PI3K inhibitors.
A study published in Cancer Epidemiology, Biomarkers & Prevention found a lower risk of breast cancer among Puerto Rican women with greater sun exposure. Researchers believe this association may be linked to the production of vitamin D and its effects on inflammation and circadian rhythms.
A Kaiser Permanente study shows that well-designed depression screening programs can effectively identify patients in need of behavioral health care and increase referrals. The program was successfully integrated into the patient care workflow of medical oncology teams, leading to improved mental health care for breast cancer patients.
Researchers at Massachusetts General Hospital found that inhibiting the OR5B21 gene significantly decreased breast cancer metastasis to the brain, bones and lung. This discovery may lead to new therapeutic targets to prevent or delay breast cancer's spread.
A new study published in the Journal of Oncology found that breast cancer patients treated at hospitals and health systems with integrative health services have a better chance of survival. These services include complementary and lifestyle therapies, such as nutrition and exercise counseling, in addition to medical cancer treatments.
A phase 1/2 clinical trial tested an L-NMMA and taxane combination in patients with chemoresistant TNBC, showing a remodeling of the immune environment in responders. The study's results warrant further investigation in larger trials to identify potential biomarkers for predicting response.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
Researchers simulated an attack that falsified mammogram images, fooling both AI breast cancer diagnosis models and human radiologist experts. The study highlights the need to develop ways to make AI models more robust to adversarial attacks, which could lead to incorrect cancer diagnoses.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.